identifi ed the common presenting symptoms of PAH as dyspnea on exertion, edema, fatigue, and chest pain; in this registry, the median time between P ulmonary arterial hypertension 1 (PAH) is an uncommon disorder characterized by abnormal increases in pulmonary artery pressure (PAP), normal pulmonary capillary wedge pressure (PCWP), and increased pulmonary vascular resistance (PVR). 2 PAH results in right ventricular pressure/volume overload leading to right ventricular failure and death. 3 Patients with PAH are often diagnosed late in the course of the disease when the pathologic changes are advanced and irreversible. [4][5][6][7] Diagnosis of PAH at this stage is associated with poor prognosis for survival, 8,9 underscoring the importance of early disease recognition and treatment. Abbreviations: 6MWD 5 6-min walk distance; LVEDP 5 left ventricular end-diastolic pressure; PAH 5 pulmonary arterial hypertension; PAP 5 pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure; PVR 5 pulmonary vascular resistance; RAP 5 right atrial pressure; REVEAL 5 Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management; RHC 5 right-sided heart catheterization